Physician profile
Mark A Jensen
NPI 1912384389
$5,451.04
in general payments reported to CMS, 2019-2025
25 companies · $798 in 2025
The $798 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,035 · 2020: $580 · 2021: $415 · 2022: $607 · 2023: $983 · 2024: $1,033 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,600 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,600.15 |
| Education | $213.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,853.61 | 2019-2025 | |
| Janssen Biotech, INC. | $1,050.53 | 2020-2025 | Stelara, Tremfya |
| Gilead Sciences, INC. | $410.83 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $359.60 | 2019-2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $326.56 | 2022-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $266.72 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $187.96 | 2019-2023 | Ocaliva |
| Genzyme Corporation | $160.45 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.75 | 2019-2025 | Xifaxan, Relistor |
| Olympus America INC. | $128.39 | 2019 | |
| Ardelyx, INC. | $92.20 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $78.88 | 2022-2024 | Suflave |
| Pfizer INC. | $75.35 | 2023-2024 | |
| Qol Medical, LLC | $49.68 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $45.53 | 2024 | Iqirvo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $38.15 | 2025 | Zenpep, Vowst |
| Nestle Healthcare Nutrition INC. | $37.76 | 2021-2022 | |
| Celgene Corporation | $34.34 | 2023 | Zeposia |
| Celltrion USA INC. | $22.25 | 2025 | Vegzelma |
| Mirum Pharmaceuticals, INC. | $20.13 | 2024 | Livmarli |
| Ironwood Pharmaceuticals, INC | $18.69 | 2020 | |
| Alexion Pharmaceuticals, INC. | $15.52 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.61 | 2023 | Seglentis |
| Shire North American Group INC | $11.46 | 2019 | |
| Janssen Pharmaceuticals, INC | $9.09 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.